In recent trading session, Cardiff Oncology Inc (NASDAQ:CRDF) saw 0.42 million shares changing hands at last check today with its beta currently measuring 1.97. Company’s recent per share price level of $4.22 trading at -$0.26 or -5.77% at last check today assigns it a market valuation of $188.74M. That most recent trading price of CRDF’s stock is at a discount of -52.13% from its 52-week high price of $6.42 and is indicating a premium of 77.73% from its 52-week low price of $0.94. Taking a look at company’s average trading volume of 1.92 million if we extend that period to 3-months.
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Upright in the red during last session for losing -5.77%, in the last five days CRDF remained trading in the green while hitting it’s week-highest on Monday, 04/29/24 when the stock touched $4.22 price level, adding 9.83% to its value on the day. Cardiff Oncology Inc’s shares saw a change of 185.24% in year-to-date performance and have moved 3.72% in past 5-day. Cardiff Oncology Inc (NASDAQ:CRDF) showed a performance of -25.55% in past 30-days.
Cardiff Oncology Inc (CRDF) estimates and forecasts
Statistics highlight that Cardiff Oncology Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 302.05% of value to its shares in past 6 months, showing an annual growth rate of -5.38% while that of industry is 12.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -18.00% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 70k for the same. And 4 analysts are in estimates of company making revenue of 70k in the next quarter. Company posted 108k and 141k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 35.42% during past 5 years.
CRDF Dividends
Cardiff Oncology Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
